Genscript Biotech Co. (OTCMKTS:GNNSF – Get Free Report)’s stock price rose 46.5% during mid-day trading on Friday . The company traded as high as C$2.93 and last traded at C$2.93. 9,078 shares traded hands during mid-day trading, an increase of 61% from the average session volume of 5,631 shares. The stock had previously closed at C$2.00.
Genscript Biotech Stock Performance
The firm’s 50-day simple moving average is C$1.71 and its 200 day simple moving average is C$1.64.
Genscript Biotech Company Profile
GenScript Biotech Corporation is a global contract research, development and manufacturing organization (CDMO) specializing in synthetic biology and biopharmaceutical services. Founded in 2002, the company provides end-to-end solutions that span gene and peptide synthesis, recombinant protein expression, custom antibody discovery and cell line development. GenScript’s integrated platforms support early-stage discovery through to process development, enabling academic institutions, biotech innovators and pharmaceutical companies to accelerate research timelines.
The company’s core offerings include molecular biology services such as DNA construction, gene editing using CRISPR/Cas9 technology and high-throughput peptide libraries.
Further Reading
- Five stocks we like better than Genscript Biotech
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Genscript Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genscript Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
